J&J rachets up R&D through 12 new alliances
- J&J is collaborating with researchers and entrepreneurs through its new innovation centers with hubs in Boston, CA, London and Shanghai.
- The focus is on early-stage technologies in areas such as cancer, diabetes, cardiovascular disease and Alzheimer’s disease.
- Many of the collaborative partnerships involve licensing agreements or direct investments in collaborating companies.
When it comes to pharmaceutical development, innovation is the driving force that leads to success, and J&J us definitely ahead of the curve. According to Paul Stoffels, Chief Scientific Officer, “The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside the current paradigms and experiment with new ways of innovating.”
Indeed, there is a great deal of innovation underway, including investigation of novel approaches to therapeutics, such as 3-D printing for trauma use, probiotics for skin infections and using brown fat to aid in the treatment of metabolic diseases.
- Pharma Times J&J Innovation highlights 12 new R&D alliances